Altimmune ALT
Altimmune Announces Update on AdCOVID TM Phase 1 Clinical Trial
- Form
- 8-K
- Filed
- Importance
- Routine
- Accession
- 0001104659-21-086854
- Makes a Regulation FD disclosure (7.01)
- Discloses other events (8.01)
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Prothena Corp Public PRTA public float $327M, Jun 30, 2025
- Usana Health Sciences USNA public float $328M, Jun 27, 2025
- Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025
- Aura Biosciences AURA public float $321M, Jun 30, 2025
- Amarin AMRN public float $335M, Jun 30, 2025
